[go: up one dir, main page]

AR056552A1 - USE OF A BETA-3 AGONIST FOR THE TREATMENT OF RENAL AND VESICULAR DISORDERS IN PATIENTS WITH SPINAL MEDULA INJURY - Google Patents

USE OF A BETA-3 AGONIST FOR THE TREATMENT OF RENAL AND VESICULAR DISORDERS IN PATIENTS WITH SPINAL MEDULA INJURY

Info

Publication number
AR056552A1
AR056552A1 ARP060104298A ARP060104298A AR056552A1 AR 056552 A1 AR056552 A1 AR 056552A1 AR P060104298 A ARP060104298 A AR P060104298A AR P060104298 A ARP060104298 A AR P060104298A AR 056552 A1 AR056552 A1 AR 056552A1
Authority
AR
Argentina
Prior art keywords
treatment
beta
result
renal
bladder
Prior art date
Application number
ARP060104298A
Other languages
Spanish (es)
Inventor
C Michel Martin
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35789109&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR056552(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR056552A1 publication Critical patent/AR056552A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se refiere al uso de agonistas del receptor adrenérgico beta-3 para la prevencion y el tratamiento de lesiones renales y/o trastornos vesiculares funcionales, en particular de lesiones de la vejiga de origen neurogeno como consecuencia de lesiones de la médula espinal. Reivindicacion 1: Uso de agonista de receptor adrenérgico beta-3, eventualmente en forma de una sal farmacéuticamente activa del mismo para la preparacion de un medicamento para la profilaxis y/o el tratamiento de lesiones renales y enfermedades renales como consecuencia de presiones elevadas patologicas o por elevadas presiones en la vejiga que resultan de una funcion erronea del detrusor. Reivindicacion 2: Uso de un agonista de receptor adrenérgico beta-3, eventualmente en forma de una sal farmacéuticamente activa del mismo para la preparacion de un medicamento para el tratamiento de enfermedades de la vejiga como consecuencia de una lesion de la médula espinal. Reivindicacion 5: Uso segun una de las reivindicaciones 1 a 4, caracterizado porque el agonista del receptor adrenérgico beta-3 se trata de un compuesto segun la formula (1) con X = H, Cl, Br, OH, metilo, Y = H, Cl, Br, OH, metilo, R = OH, metoxi, etoxi o una sal farmacéuticamente aceptable del mismo. Reivindicacion 17: Método para el tratamiento o la profilaxis de lesiones renales y enfermedades renales como consecuencia de presiones elevadas patologicas o por presiones elevadas en la vejiga, resultantes de una suncion erronea del detrusor en el que se utiliza un medicamento conforme a una de las reivindicaciones precedentes. Reivindicacion 18: Método para el tratamiento de enfermedades de la vejiga como consecuencia de una lesion de la médula espinal, de enfermedades de la vejiga como consecuencia de una enfermedad de Parkinson, de una enfermedad de Alzheimer, de un trauma craneoencefálico o de esclerosis multiple, en el que se utiliza un medicamento conforme a una de las reivindicaciones precedentes.It refers to the use of beta-3 adrenergic receptor agonists for the prevention and treatment of renal lesions and / or functional vesicular disorders, in particular of bladder lesions of neurogenic origin as a result of spinal cord injuries. Claim 1: Use of beta-3 adrenergic receptor agonist, possibly in the form of a pharmaceutically active salt thereof for the preparation of a medicament for the prophylaxis and / or treatment of renal lesions and renal diseases as a result of pathological elevated pressures or due to high bladder pressures resulting from an erroneous detrusor function. Claim 2: Use of a beta-3 adrenergic receptor agonist, possibly in the form of a pharmaceutically active salt thereof for the preparation of a medicament for the treatment of bladder diseases as a result of a spinal cord injury. Claim 5: Use according to one of claims 1 to 4, characterized in that the beta-3 adrenergic receptor agonist is a compound according to formula (1) with X = H, Cl, Br, OH, methyl, Y = H , Cl, Br, OH, methyl, R = OH, methoxy, ethoxy or a pharmaceutically acceptable salt thereof. Claim 17: Method for the treatment or prophylaxis of renal lesions and renal diseases as a result of high pathological pressures or high bladder pressures, resulting from an erroneous dejection of the detrusor in which a medicament according to one of the claims is used precedents Claim 18: Method for the treatment of bladder diseases as a result of spinal cord injury, bladder diseases as a result of Parkinson's disease, Alzheimer's disease, craniocerebral trauma or multiple sclerosis, wherein a medicament according to one of the preceding claims is used.

ARP060104298A 2005-09-30 2006-09-29 USE OF A BETA-3 AGONIST FOR THE TREATMENT OF RENAL AND VESICULAR DISORDERS IN PATIENTS WITH SPINAL MEDULA INJURY AR056552A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05021420A EP1769792A1 (en) 2005-09-30 2005-09-30 Use of a beta-3 adrenoceptor agonist for the treatment of renal and bladder problems

Publications (1)

Publication Number Publication Date
AR056552A1 true AR056552A1 (en) 2007-10-10

Family

ID=35789109

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060104298A AR056552A1 (en) 2005-09-30 2006-09-29 USE OF A BETA-3 AGONIST FOR THE TREATMENT OF RENAL AND VESICULAR DISORDERS IN PATIENTS WITH SPINAL MEDULA INJURY

Country Status (5)

Country Link
US (1) US20070078181A1 (en)
EP (1) EP1769792A1 (en)
AR (1) AR056552A1 (en)
TW (1) TW200730169A (en)
WO (1) WO2007036543A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009019599A2 (en) * 2007-08-08 2009-02-12 Themis Laboratories Private Limited Extended release compositions comprising tolterodine
TWI478712B (en) 2008-09-30 2015-04-01 Astellas Pharma Inc Pharmaceutical composition for modified release
BE1018452A3 (en) 2008-10-31 2010-12-07 Tessenderlo Chemie N V S A METHOD FOR THE MANUFACTURE OF PRE-REINFORCED AND REINFORCED PVC POLYMERS AND APPARATUS thereof.
US9522129B2 (en) 2010-08-03 2016-12-20 Velicept Therapeutics, Inc. Pharmaceutical Combination
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
AU2011285928B9 (en) 2010-08-03 2018-08-02 B3Ar Therapeutics, Inc. Combinations of beta - 3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder
EP3226849A4 (en) 2014-12-03 2018-05-09 Velicept Therapeutics, Inc. Compositions and methods of using modified release solabegron for lower urinary tract symptoms
US10065922B2 (en) 2015-10-23 2018-09-04 Velicept Therapeutics, Inc. Solabegron zwitterion and uses thereof
US12097189B1 (en) 2024-02-09 2024-09-24 Astellas Pharma Inc. Pharmaceutical composition for modified release

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4685201B2 (en) 1996-08-19 2011-05-18 キッセイ薬品工業株式会社 Preventive and therapeutic agent for frequent urination and incontinence
ID24062A (en) * 1997-07-25 2000-07-06 Kissei Pharmaceutical AMINOETYLPHENOCETHETIC ACID AND DRUG ACQUINITIES TO REDUCE PAIN AND HELP IMPROVEMENT IN DAILY WATER LITIASIS
MY126489A (en) 1998-07-08 2006-10-31 Kissei Pharmaceutical Phenoxyacetic acid derivatives and medicinal compositions containing the same
DE19935209A1 (en) * 1999-07-27 2001-02-08 Truss Michael C Treatment of urinary incontinence and related disorders, by increasing intracellular cyclic adenosine monophosphate concentration, e.g. using adenyl cyclase stimulant such as forskolin
HRP20040250A2 (en) 2001-09-13 2005-02-28 Kissei Pharmaceutical Co.Ltd. Crystals of hydroxynorephedrine derivative
EP1424079A1 (en) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine
MXPA05011862A (en) * 2003-05-05 2006-02-17 Kissei Pharmaceutical Use of phenoxyacetic acid derivatives for treating hyperactive bladder.
DE10351271A1 (en) * 2003-10-31 2005-06-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical composition for the treatment of stress incontinence and / or mixed incontinence
CA2544100A1 (en) * 2003-11-03 2005-05-12 Boehringer Ingelheim International Gmbh Pharmaceutical composition, containing a beta-3-adrenoceptor agonist and an alpha antagonist and/or a 5-alpha-reductase inhibitor
DE10352132A1 (en) * 2003-11-04 2005-06-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical composition of a beta-3 adrenoceptor agonist and an alpha agonist
DE10356112A1 (en) * 2003-11-27 2005-06-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg A pharmaceutical composition of a beta-3 adrenoceptor agonist and a progglandin metabolite
WO2005092321A1 (en) * 2004-03-24 2005-10-06 Kissei Pharmaceutical Co., Ltd. Pharmaceutical composition for prevention or treatment of increased urinary frequency or involuntary urination

Also Published As

Publication number Publication date
WO2007036543A8 (en) 2007-12-27
TW200730169A (en) 2007-08-16
WO2007036543A1 (en) 2007-04-05
EP1769792A1 (en) 2007-04-04
US20070078181A1 (en) 2007-04-05

Similar Documents

Publication Publication Date Title
CO5640076A2 (en) PHARMACEUTICAL COMPOSITION INCLUDED BY AN IBAT INHIBITOR FOR THE TREATMENT OR PROFILAXIS OF THE CONSTIPATION
ES2611483T3 (en) Therapeutic agent for inflammatory bowel disease
BR112012018386A8 (en) "phosphatidylinositol 3-kinase isoindolinone inhibitors"
MX2009001660A (en) 2,5-DIHYDROXIBENGEN COMPOUNDS FOR THE TREATMENT OF PSORIASIS.
WO2010135396A3 (en) Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
WO2006076620A3 (en) Bendamustine pharmaceutical compositions for lyophilisation
JP2013519675A5 (en)
WO2009066152A3 (en) Haloallylamine inhibitors of ssao/vap-1 and uses therefor
MX2009002239A (en) 5- (2-furyl)-1, 3-thiazole derivatives useful as inhibitors of phosphatidylinositol 3-kinase.
AR079208A2 (en) INHIBITORS OF THE ACTIVITY OF PROTEIN THYROSINE KINASE, COMPOSITION AND USE OF SUCH INHIBITORS FOR THE PREPARATION OF A MEDICINAL PRODUCT TO TREAT A DISEASE, DISORDER OR OPHTHALMIC CONDITION
CL2012003171A1 (en) Compounds derived from cyclohexylamine, with dual agonist activity with the m3 muscarinic receptor and agonist with the b2 adrenergic receptor; pharmaceutical composition comprising a compound; combination; pharmaceutical; and its use of a compound in the preparation of respiratory disease medication.
AR056552A1 (en) USE OF A BETA-3 AGONIST FOR THE TREATMENT OF RENAL AND VESICULAR DISORDERS IN PATIENTS WITH SPINAL MEDULA INJURY
FI3504187T3 (en) Use of pridopidine for treating functional decline
CL2012000708A1 (en) Compounds derived from imidazopyridine or imidazopyrimidine, inhibitors of pde10a; process of preparation of said compounds; pharmaceutical compositions; and its use for the therapeutic and / or preventive treatment of psychotic disorders, schizophrenia, Alzheimer's disease, solid tumors, among other diseases.
WO2008154083A3 (en) Compounds, compositions and methods for the treatment of synucleinopathies
AR079706A1 (en) COMPOSITIONS, METHODS FOR THE TREATMENT OF EYE DISEASES RELATED TO ANGIOGENESIS AND USE
MA30556B1 (en) DIALKYLPHENYL-BASED COMPOUNDS HAVING AGONIST ACTIVITY OF THE β2 ADRENERGIC RECEPTOR AND ANTAGONIST OF THE MUSCARIN RECEPTOR.
AR062390A1 (en) USE OF DERIVATIVES OF 2,5-DIHYDROXIBENGEN FOR THE TREATMENT OF HEMANGIOMS OR HEMANGIOBLASTOMAS
BRPI0507544A (en) combination of benzothiazole-2-one beta-2 adrenoreceptor agonists and corticosteroids for the treatment of respiratory diseases
JP2008513510A5 (en)
WO2006077025A3 (en) Morpholines as 5ht2c agonists
DOP2005000039A (en) HYDROCHLORIDE OF [4- (5-AMINOMETIL-2-FLUORO-PHENYL) - PIPERIDIN-1-IL] - (4-BOMO-3-METHYL-5-PROPOXI-TIOFEN-2-IL) -METANONE AS AN INHIBITOR OF THE MASTOCYT TRIPTASE
MY156278A (en) Disubstituted [4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones
CO6331429A2 (en) DERIVATIVES OF 5- (4-METHANOSULPHONYL-PHENYL) -TIAZOL FOR THE TREATMENT OF ACUTE AND CHRONIC INFLAMMATORY DISEASES
HRP20110459T1 (en) USE OF 4-CYCLOPROPYLMETOXY-N- (3,5-DICHLOR-1-OXIDOPYRIDIN-4-IL) -5- (METHOXY) PIRIDINE-2-CARBOXAMIDE IN THE TREATMENT OF SPINAL DAMAGE

Legal Events

Date Code Title Description
FA Abandonment or withdrawal